Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2010
June 2010, Vol 1, No 2
June 2010, Vol 1, No 2
Genetic Testing as Simple as 1-2-3
Genetic Testing
,
IMPAKT Breast Cancer Conference
,
Personalized Medicine
June 2010, Vol 1, No 2
Brussels—A simple genetic test using only 3 genes is among the most effective means of classifying breast cancer into the subtypes that indicate pa tients’ different prognoses and response or resistance to cancer therapies, say researchers, and this finding could allow greater use of personalized treatments in breast cancer.
Read Article
Better Targeting for Targeted Therapy
IMPAKT Breast Cancer Conference
June 2010, Vol 1, No 2
Brussels—Researchers attempting to understand why some women with human epidermal growth factor receptor 2 (HER2)–positive breast cancer do not respond to drugs designed to target this molecule have found that inhibiting the PI3K/AKT molecular pathway instead may offer greater therapeutic benefit for this group. The findings were presented at the IMPAKT [Improving Care and Knowledge Through Translational Research] Breast Cancer Conference, held May 5-8.
Read Article
Pemetrexed as Maintenance Therapy Likely to Have ‘Minimal Impact’ on Health Plan Budget
AMCP Annual Meeting
June 2010, Vol 1, No 2
San Diego—In the first study to estimate the budgetary impact of accepting pemetrexed as maintenance therapy for non–small-cell lung cancer (NSCLC), researchers found that adopting the drug did not significantly affect a health plan’s budget.
Read Article
Researchers Analyze Relationship Between Pharmacogenomics and Appropriate Oncology Care
AMCP Annual Meeting
June 2010, Vol 1, No 2
San Diego—Pharmacogenomic (PGx) testing seeks to optimize treatment by ensuring patients receive the bestsuited drug based on interindividual genetic variation. Currently, no published data exist on how this may influence the appropriateness of oncology treatment within a utilization management program. Seeking to remedy this, researchers from CVS Caremark (Northbrook, IL) analyzed data from their own utilization management program, within which PGx testing requirements are implemented for certain oncology therapies and specific indications.
Read Article
Survey Provides a Window Into Payers’ Decision-Making Process
AMCP Annual Meeting
June 2010, Vol 1, No 2
San Diego—Payers believe that prescribing information, national guidelines, and prospective controlled randomized trials (PCRTs) are the most useful sources of information about oncology drugs, according to researchers from Genentech, Inc (South San Francisco).
Read Article
Patients More Likely to Abandon Drug Therapy When Paying More Out of Pocket
AMCP Annual Meeting
June 2010, Vol 1, No 2
San Diego—For health plans attempting to cut costs, instituting higher out-of-pocket (OOP) payments for patients taking oral oncology drugs may not be a prudent solution, according to research presented at the AMCP’s annual meeting.
Read Article
Managed Care Pharmacist Boosts Drug Replacement, Reimbursement
AMCP Annual Meeting
June 2010, Vol 1, No 2
Presenting the findings at the annual meeting of the AMCP, lead researcher Shetal Desai, PharmD, discussed how NCH decreased the number of disputed claims and recovered more than $1 million in drug replacement from manufacturer patient-assistance programs across 18 months after bringing a managed care pharmacist on board.
Read Article
Variant Methodology Impedes Cost-effectiveness Research
AMCP Annual Meeting
June 2010, Vol 1, No 2
San Diego—Despite increasing interest in cost-effectiveness (CE) research, the groups conducting these analyses continue to use models that are very different from each other, hampering a more precise understanding of drug comparability.
Read Article
CER: Use, Controversy Both Growing
Comparative Effectiveness Research
,
VBCC Perspectives
June 2010, Vol 1, No 2
Even before enactment of national healthcare reform initiatives, development and implementation of a variety of comparative effectiveness research (CER) was well under way, even if it was not specifically called comparative effectiveness.
Read Article
Reaching for Consistency with Genetic Testing
By
Winston Wong, PharmD
Value-Based Care
,
VBCC Perspectives
June 2010, Vol 1, No 2
Recent articles in the
New England Journal of Medicine
1
and the
Journal of the American Medical Association
2
note the tremendous increase in the cost of cancer care, which has at least doubled since 1990. The reasons for this steep increase have been attributed to the release and utilization of new medications, in tandem with more sophisticated surgery and radiation techniques.
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma